🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07273877
Enrolling by invitation Observational

"Real-world Assessment of BP Control in Patients With Hypertension by the Netrod RDN System" - REACH-RDN

NCT07273877 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Golden Leaf MedTec Co. Ltd
Phase
Observational
Started
2025-08-07
Last updated
2026-04-20

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

Percutaneous nephrolysis combined with sympathetic nerve ablation (RDN) procedure

Percutaneous nephrolysis combined with sympathetic nerve ablation (RDN) procedure: The disposable mesh renal artery radiofrequency ablation catheter is a spiral-arranged 6-point mesh system. Once The use of a meshed renal artery radiofrequency ablation catheter in combination with a dedicated renal artery radiofrequency ablation device delivers radiofrequency energy to the inner wall of the renal artery, generating appropriate high temperatures to damage or partially damage the renal sympathetic nerves. This device has real-time temperature, power and impedance monitoring functions, providing real-time ablation feedback. It also has the function of real-time recording of ablation data and saving the data.

Study summary

This study is an observational one, collecting real-world data generated in routine clinical treatment. The Netrod-RDN renal artery radiofrequency ablation system (including the renal artery radiofrequency ablation device and the disposable mesh renal artery radiofrequency ablation catheter) produced and provided by Shanghai Meiliweiye Medical Technology Co., Ltd. was used to perform percutaneous renal denervation (RDN) on patients with refractory hypertension and drug intolerance in the real world. Refractory hypertension is defined as patients whose blood pressure remains uncontrolled despite taking three or more antihypertensive drugs (including one diuretic) for more than three months; drug intolerance refers to patients who have contraindications to drugs or cannot tolerate drug administration due to adverse drug reactions.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * (1) Patients who have already used or are planning to use the Netrod-RDN renal artery radiofrequency ablation system for RDN surgery; * (2) Patients understand the requirements and treatment of this clinical study, agree to follow the requirements of this clinical study for follow-up, and sign the informed consent form before undergoing any special examinations and operations related to the study. Exclusion Criteria: * Patients with contraindications for RDN surgery and/or those who the researchers consider unsuitable for RDN or who do not wish to participate in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Capital Medical University Beijing Anzhen Hospital Beijing Beijing Municipality

More Shanghai Golden Leaf MedTec Co. Ltd trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07273877 on ClinicalTrials.gov ↗ ← All trials in China